A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

NCT04450394 PHASE2 COMPLETED Results posted

The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes.

Details

Lead sponsor	Eli Lilly and Company
Phase	PHASE2
Status	COMPLETED
Enrolment	278
Start date	Wed Jul 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Oct 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Type 2 Diabetes Mellitus

Interventions

• LY3209590
• Insulin Degludec

Countries

Germany, Poland, Argentina, Puerto Rico, United States